This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Jessica Anne Clarke, MD, PhD
University of California at Davis Medical Center Sacramento, Calif

F. Blaine Hollinger, MD
Baylor College of Medicine Houston, Tex

JAMA. 1990;264(2):182.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.—

We applaud the well-designed study by Wiström et al that demonstrates that low-dose ID inoculation of adults with three 2-µg doses of a recombinant hepatitis B vaccine (Recombivax-HB, Merck Sharp & Dohme) results in lower seroconversion rates and reduced levels of antibody to HBsAg compared with three 10-µg IM injections of the same product.

These results are not unexpected. There is a positive correlation between dose and immune response regardless of the type of product used.¹ In our ID study we were able to use the more immunogenic plasma-derived Hepta . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?